Quality of Life Linked with Physical, Psychological Symptoms in Cancer
the Cancer Therapy Advisor take:
Quality of life (QoL) was found to be linked to physical and psychological symptoms in patients with advanced cancer, according to an article published online in the journal European Journal of Cancer Care.
In this study, 115 patients with cancer were evaluating using a series of rating scales including the Functional Assessment of Chronic Illness Therapy – Spiritual Well-Being Scale, the Hospital Anxiety and Depression Scale, the Visual Analogue Scale for pain, the Brief Coping Orientation to Problem Experienced and the Functional Assessment of Cancer Therapy Scale – General Measure.
Results showed workers and single patients with higher level education demonstrated a worse QoL compared to their counterparts.
Furthermore, QoL was negatively associated with pain and anxiety, but positively associated with spirituality and ‘Instrumental Support’ coping style.
The authors noted that when patients were close to death in the Italian sample, they relied heavily on faith as a component of spirituality rather than meaning or peace.
Quality of life was found to be linked to physical and psychological symptoms in patients with advanced cancer.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Immune Checkpoint Inhibitors for NSCLC: Current and Future Approaches
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- Can A Consortium of Hospitals Help To Reduce Drug Prices?
- Erdafitinib Granted FDA Breakthrough Therapy Designation for Urothelial Carcinoma
- NSCLC: Stratifying Patients With Complex EGFR Mutations
- Nivolumab Plus Ipilimumab Improves Overall Survival, ORR in Renal Cell Carcinoma
- Encorafenib, Binimetinib May Be Effective in BRAF-Mutant Melanoma
- CLL: Venetoclax Plus Rituximab Improves 2-Year PFS
- Confronting Racial Disparities in Prostate Cancer Survival Outcomes
- FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma